With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.314741-39-4,(S)-1-tert-Butyl 3-methyl piperazine-1,3-dicarboxylate,as a common compound, the synthetic route is as follows.
Combine 2-Chloro-4-trifluoromethyl-pyrimidine-5-carboxylic acid methyl ester (240mg, 1.70 mmol), (5)-piperazine-l,3-dicarboxylic acid 1-tert-butyl ester 3 -methyl ester (2.04 mmol) and triethylamine (5.11 mmol) in a 0.85 M solution of dioxane. Microwave reaction mixture for 30 min at 150 0C. Filter reaction mixture and rinse with acetonitrile. Purify filtrate by column chromatography in a 0-70% ethyl acetate/heptane gradient to give (1S)-4-(5-Methoxycarbonyl-4-trifluoromethyl-pyrimidin-2-yl)-piperazine- 1,3- dicarboxylic acid 1-tert-butyl ester 3 -methyl-ester contaminated with approximately 15 % of the mono hydrolysis product. The mixture is carried on to next step without further purification. (61% yield)
As the paragraph descriping shows that 314741-39-4 is playing an increasingly important role.
Reference£º
Patent; NOVARTIS AG; WO2008/110611; (2008); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics